Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRX-100 single ascending dose in healthy volunteers
NCT06757738Phase 1Completed
- Sponsor
- Traws Pharma, Inc.
- Start
- Aug 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tivoxavir marboxil (4 arms), sponsored by Traws Pharma, Inc. Primary endpoint: Safety and tolerability of single oral administration of TRX-100 at 28 days. Started Aug 2024; status: completed.
02
Drugs
tivoxavir marboxil
Beyond the preview
Go deeper on NCT06757738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06757738.